X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS NATCO PHARMA DR. DATSONS LABS/
NATCO PHARMA
 
P/E (TTM) x -10.9 16.7 - View Chart
P/BV x 0.2 18.0 0.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 DR. DATSONS LABS   NATCO PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
NATCO PHARMA
Mar-14
DR. DATSONS LABS/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs126877 14.3%   
Low Rs31424 7.3%   
Sales per share (Unadj.) Rs133.0223.4 59.5%  
Earnings per share (Unadj.) Rs0.231.1 0.5%  
Cash flow per share (Unadj.) Rs6.640.3 16.4%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs128.8219.5 58.7%  
Shares outstanding (eoy) m31.6633.07 95.7%   
Bonus/Rights/Conversions FCCBPA-  
Price / Sales ratio x0.62.9 20.2%   
Avg P/E ratio x516.120.9 2,465.9%  
P/CF ratio (eoy) x11.816.1 73.3%  
Price / Book Value ratio x0.63.0 20.5%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m2,47721,504 11.5%   
No. of employees `000NANA-   
Total wages/salary Rs m561,128 5.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m4,2117,389 57.0%  
Other income Rs m79167 47.1%   
Total revenues Rs m4,2897,556 56.8%   
Gross profit Rs m5691,793 31.7%  
Depreciation Rs m204304 67.1%   
Interest Rs m430366 117.5%   
Profit before tax Rs m131,290 1.0%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6309 2.0%   
Profit after tax Rs m51,027 0.5%  
Gross profit margin %13.524.3 55.6%  
Effective tax rate %48.023.9 200.7%   
Net profit margin %0.113.9 0.8%  
BALANCE SHEET DATA
Current assets Rs m6,8523,681 186.1%   
Current liabilities Rs m6,7113,123 214.9%   
Net working cap to sales %3.37.6 44.3%  
Current ratio x1.01.2 86.6%  
Inventory Days Days16189 179.8%  
Debtors Days Days31859 542.7%  
Net fixed assets Rs m3,6737,685 47.8%   
Share capital Rs m317331 95.7%   
"Free" reserves Rs m3,7616,670 56.4%   
Net worth Rs m4,0787,259 56.2%   
Long term debt Rs m1,671955 175.0%   
Total assets Rs m12,63311,957 105.6%  
Interest coverage x1.04.5 22.8%   
Debt to equity ratio x0.40.1 311.5%  
Sales to assets ratio x0.30.6 53.9%   
Return on assets %3.411.7 29.5%  
Return on equity %0.114.2 0.8%  
Return on capital %7.720.7 37.0%  
Exports to sales %22.939.4 58.2%   
Imports to sales %14.35.7 250.8%   
Exports (fob) Rs m9642,908 33.2%   
Imports (cif) Rs m602421 142.9%   
Fx inflow Rs m9643,445 28.0%   
Fx outflow Rs m607703 86.4%   
Net fx Rs m3572,743 13.0%   
CASH FLOW
From Operations Rs m1,3451,440 93.4%  
From Investments Rs m-2,256-1,089 207.1%  
From Financial Activity Rs m-1,200-353 340.2%  
Net Cashflow Rs m-2,111-1 141,657.7%  

Share Holding

Indian Promoters % 4.5 52.0 8.7%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 0.0 7.8 -  
FIIs % 1.4 16.6 8.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 26.0 361.9%  
Shareholders   20,807 25,395 81.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

Bharat Dynamics IPO: Worth Betting on Defence Manufacturing? (IPO)

Mar 12, 2018

Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - GSK PHARMA COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS